progesterone
progesterone
Overview
Progesterone is a steroid hormone and a clinically important pharmaceutical agent that acts through progesterone receptors to regulate reproductive physiology, including ovulation, implantation, pregnancy maintenance, and endometrial differentiation. In medicine, it is used in a range of hormonal and gynecologic contexts, and it is also investigated as a delivery target for formulations designed to improve local or sustained exposure.
Beyond reproductive biology, progesterone has been studied in relation to broader endocrine and tissue-specific effects, including potential roles in ocular, neurologic, and metabolic settings. Recent research has therefore focused not only on its biological activity, but also on how to deliver it more precisely using advanced drug-delivery platforms such as 3D-printed inserts, vaginal rings, microneedle patches, and nanoparticle-based systems.
Focus of Latest Publications
Recent publications have examined progesterone primarily as a therapeutic target for controlled delivery and as a biomarker or hormone of interest in reproductive and systemic physiology.
Several studies focused on formulation and delivery engineering. One ex vivo study investigated progesterone delivered to the eye using 3D-printed inserts, with the goal of achieving sustained delivery for retinal diseases related to oxidative stress. This work emphasized diffusion and biodistribution in ocular tissues, supporting the idea that localized delivery may improve exposure at the target site while limiting systemic effects.
In vaginal drug delivery, progesterone was studied in multiple advanced dosage forms. A dual-responsive ionic liquid-based foam-to-gel system, termed IL-FOAM, was developed for precision vaginal delivery of progesterone. Another study used material extrusion additive manufacturing to produce 3D polyurethane vaginal rings that released clinically relevant quantities of progesterone over 28 days. These studies collectively highlight ongoing efforts to maintain prolonged, controlled hormone release using formulations designed for mucosal administration.
Transdermal delivery was also explored. One study developed AI-assisted 3D-printed degradable hydrogel microneedles for transdermal delivery of progesterone-loaded solid lipid nanoparticles, with the stated aim of slowing Alzheimer’s disease progression. The publication framed progesterone as a candidate used to slow neurodegenerative disease progression, particularly in postmenopausal women, and combined it with nanoparticle and microneedle technologies to improve skin penetration and sustained delivery.
Progesterone also appeared in reproductive and endocrine research as a physiological marker. A machine-learning study aimed to predict early pregnancy outcomes using baseline levels and dynamic changes in β-human chorionic gonadotropin, progesterone, and estradiol. This indicates that progesterone remains clinically relevant as part of multimarker assessment in early gestation. In another study, prostaglandin D2 was reported to reinforce mitochondrial quality control and enhance ovarian and embryonic competence; concomitantly, it promoted steroidogenic activation, with increased StAR and CYP11A1 expression and significantly elevated estradiol and progesterone secretion in human granulosa-related experimental systems. This places progesterone within the broader context of ovarian steroidogenesis and embryo-supportive physiology.
A separate study on cholesteryl ester accumulation in endometrioid endometrial carcinoma found that only about half of patients respond to first-line progesterone therapy, and identified a biomarker to help personalize fertility-preserving therapy selection during the six-month treatment window.
Finally, a case report described uterine angiosarcoma diagnosed by endometrial pipelle biopsy and noted the effect of oral progesterone treatment on associated lung metastases. During oral progesterone therapy for abnormal uterine bleeding, lung metastases initially regressed before later progressing. This report underscores that progesterone may be used clinically in complex gynecologic settings, while also illustrating that observed responses can be variable and disease-specific.
Additional research context included a study on overnight wakefulness and next-day postprandial glucose in young women, which noted that estradiol and progesterone may influence glucose regulation, although the study aimed to determine whether ovarian hormone levels modulate night shift-induced impairments in glucose metabolism. This reflects ongoing interest in progesterone as part of endocrine interactions affecting metabolic homeostasis.